Israel
Chemomab Therapeutics, a clinical stage biotechnology company, is focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. The company's flagship product, CM-101, a monoclonal antibody targeting the chemokine CCL24, has shown promising results in preclinical and clinical studies. With its potential to treat severe and life-threatening conditions, such as NASH and severe lung injury, CM-101 has garnered attention.
Founded in 2011 and headquartered in Israel, Chemomab recently secured a significant $45.50M Post-IPO Equity investment on 16 March 2021. The investment was led by OrbiMed, Apeiron Investment Group, Cormorant Asset Management, Presight Capital, and prominent investor Peter Thiel. This funding indicates strong support and confidence in the potential of Chemomab's pipeline and CM-101's therapeutic efficacy.
Overall, Chemomab Therapeutics stands at the forefront of addressing unmet medical needs in fibro-inflammatory diseases, backed by substantial financial support and a promising developmental trajectory for CM-101.
